Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | DRD4 | P21917 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17481989 | 0.83 | DRD2 (0.39) | ALDH1A1ADRB1ADRB2DRD2DRD4 | |
| SCHEMBL8211174 | 0.83 | DRD2 (0.39) | ALDH1A1ADRB1ADRB2DRD2DRD4 | |
| SCHEMBL17481987 | 0.80 | DRD2 (0.33) | ALDH1A1MAPTADRB1ADRB2DRD2 | |
| SCHEMBL17484547 | 0.78 | ADRB2 (0.39) | ALDH1A1MAPTADRB1ADRB2DRD2 | |
| SCHEMBL11912374 | 0.77 | DRD2 (0.42) | ALDH1A1ADRB1ADRB2DRD2DRD4 | |
| SCHEMBL1559916 | 0.75 | ADRB2 (0.39) | ALDH1A1MAPTADRB1ADRB2DRD2 | |
| SCHEMBL17476304 | 0.75 | SMYD3 (0.56) | ALDH1A1MAPTDRD2GAASMYD3 | |
| SCHEMBL6428975 | 0.72 | DRD2 (0.42) | ALDH1A1ADRB1ADRB2DRD2DRD4 | |
| SCHEMBL8523943 | 0.71 | ALDH1A1 (0.34) | ALDH1A1MAPT | |
| SCHEMBL9909524 | 0.69 | DRD2 (0.58) | ADRB1ADRB2DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598381-B2 | SMYD2 inhibitors | ABBVIE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160031838-A1 | SMYD2 INHIBITORS | ABBVIE INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031838-A1 | SMYD2 INHIBITORS | SMYD2, SMYD3, NSD1 | ALDH1A1 3870/4885MAPT 2177/4885ADRB1 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.